Mirikizumab was found safe and effective for induction and maintenance of moderately to severely active ulcerative colitis in the phase 3 LUCENT-1 and LUCENT-2 trials.
Presenting the LUCENT-1 induction trial results at the 2022 virtual Congress of the European Crohn’s and Colitis Organisation, Geert D’Haens, MD, PhD, from Amsterdam University Medical Centers, and his co-investigators reported that mirikizumab (Lilly) “demonstrated statistically significant and clinically